Keywords: novartis, ups, bid, remainder, chiron, share, rebels

Novartis ups bid for remainder of Chiron to $48 a share, which rebels will accept

Article | 10 April 2006

Print This

Swiss pharmaceutical major Novartis looks set to complete the acquisition of the 56% of shares in US biotechnology/vaccines firm Chiron ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in